Status:
ACTIVE_NOT_RECRUITING
LEVANTIS-0093A: GAGomes for Multi-Cancer Early Detection in High-Risk Adults (LEV93A)
Lead Sponsor:
Elypta
Conditions:
Cancer
Eligibility:
All Genders
55-80 years
Brief Summary
LEVANTIS-0093A (LEV93A) is a prospective cohort observational clinical study to validate the plasma free GAGome MCED test in adults at high risk of developing cancer ("high-risk adults"), specifically...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Adults aged 55-80 years old
- Significant smoking history, defined as current or ex-smokers and any of the following criteria:
- 30 pack year history of smoking and current smoker or quit within the last 15 years (USPSTF criteria).
- Lung cancer risk of ≥1.51% over 6 years as calculated by the PLCOM2012 score
- Lung cancer risk of ≥5% over 5 years as calculated by the LLPv2. Score
- Consenting to participate to both YLST and YLST Biomarker trials
- Able to donate a blood sample
- Exclusion Criteria
- Deemed medically unfit for sample collection
- Contraindication for study procedures or sampling
- Not consenting to participate to YKST trial
Exclusion
Key Trial Info
Start Date :
March 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2026
Estimated Enrollment :
1235 Patients enrolled
Trial Details
Trial ID
NCT05295017
Start Date
March 14 2022
End Date
March 1 2026
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leads Teaching Hospitals Trust
Leeds, United Kingdom